Welcome to our dedicated page for Galmed Pharmaceu news (Ticker: GLMD), a resource for investors and traders seeking the latest updates and insights on Galmed Pharmaceu stock.
Galmed Pharmaceuticals Ltd. (GLMD) is a clinical-stage biopharmaceutical company advancing innovative therapies for liver, metabolic, and fibro-inflammatory diseases. This news hub provides investors and industry professionals with timely updates on the company's lead compound Aramchol, a novel SCD1 inhibitor being evaluated in late-stage clinical trials for non-alcoholic steatohepatitis (NASH).
Access official press releases and curated analysis covering clinical developments, regulatory milestones, and strategic partnerships. Our repository includes updates on Aramchol's unique mechanism of action targeting hepatic fat metabolism, patent filings for combination therapies, and progress in addressing complex liver pathologies.
Key content categories include clinical trial results, FDA communications, financial reporting disclosures, and scientific conference presentations. Bookmark this page for centralized access to Galmed's evolving research initiatives and business developments in the competitive NASH therapeutics landscape.
Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) has filed its Annual Report on Form 20-F for the fiscal year ending December 31, 2022, with the SEC. The report details their development of Aramchol for liver diseases and includes risks associated with clinical trials and regulatory approvals. Shareholders can access the report via the SEC and the company's Investor Relations website. Galmed remains focused on advancing Aramchol and collaborating on the development of other therapies, including Amilo-5MER.
Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) announced that the U.S. Patent and Trademark Office granted patent 11,571,431 B2, extending Aramchol's exclusivity to December 2034. This patent protects Aramchol's use, particularly in treating NASH and Fibrosis, and fortifies its existing patent portfolio, which now encompasses over 20 issued patents worldwide. The N-methylglucamine salt form, noted for its advantageous properties, enhances absorption and bioavailability. CEO Allen Baharaff emphasized that this patent strengthens their ability to maximize Aramchol's therapeutic potential across various indications.
Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) announced significant findings from the ARMOR study regarding their treatment Aramchol for NASH. The study revealed a 39% improvement in fibrosis and a 61% improvement based on ranked assessments. Key results included a highly statistically significant reduction in liver stiffness and liver injury markers (ALT and AST), all showing p-values <0.0001. Galmed plans to submit this data to the FDA for consideration of advanced histology reading methodologies as primary endpoints in future NASH studies.
FAQ
What is the current stock price of Galmed Pharmaceu (GLMD)?
What is the market cap of Galmed Pharmaceu (GLMD)?
